Alan Ezekowitz - 26 Jun 2026 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Reporting relationship: Director
Issuer ticker: FULC
Reported as of: 26 Jun 2026
Net transaction value: -$65,614
SEC form: 4
Accepted by SEC: 30 Jun 2026, 16:30:02 UTC
Prior SEC filing: 15 Jun 2026
Next SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Greg Tourangeau, as attorney-in-fact for Alan Ezekowitz

Key filing fact

Alan Ezekowitz filed Form 4 for Fulcrum Therapeutics, Inc. (FULC) on 30 Jun 2026.

Key facts

This page summarizes Alan Ezekowitz's Form 4 filing for Fulcrum Therapeutics, Inc. (FULC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: -$65,614.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780209 Primary reporting owner

Ezekowitz Alan

Relationship: Director
Address: C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE
Signature: /s/ Greg Tourangeau, as attorney-in-fact for Alan Ezekowitz
Signature date: 30 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FULC transaction

Common Stock

Sale

Transaction value: $65,614
Shares: -18,000
Change %: -62%
Price: $3.65
Shares after: 10,927
Date: 26 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.555 to $3.82, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.